James Peyer - 21 May 2025 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: SNSE
Reported as of: 21 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 May 2025, 16:30:15 UTC
Prior SEC filing: 13 Jun 2024
Next SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ James Peyer

Key filing fact

James Peyer filed Form 4 for Sensei Biotherapeutics, Inc. (SNSE) on 23 May 2025.

Key facts

This page summarizes James Peyer's Form 4 filing for Sensei Biotherapeutics, Inc. (SNSE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 May 2025, 16:30.

Change

Previous filing in this sequence was filed on 13 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001843594 Primary reporting owner

Peyer James

Relationship: Director, 10%+ Owner
Address: 228 PARK AVENUE S. #66643, NEW YORK
Signature: /s/ James Peyer
Signature date: 23 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNSE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +19,000
Change %
Price: $0.000000
Shares after: 19,000
Date: 21 May 2025
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 19,000
Exercise price: $0.3202
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Footnote F2

These options are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the options, and shares exercisable thereunder, held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such options.